United Therapeutics Reports Tomorrow With Analysts Bracing for Another Estimate Miss
United Therapeutics Corporation (UTHR) reports second-quarter 2026 earnings before market open on August 5, 2026, with analysts expecting $6.82 per share—a year-over-year improvement but against a backdrop of recent volatility. The central question: can the biotechnology company reverse last quarter's sharp miss and restore confidence in its pulmonary arterial hypertension (PAH) franchise? With the stock trading at $518.68 and technical indicators weakening, this report will test whether UTHR's growth trajectory remains intact or if operational headwinds are mounting.
Part 1: Earnings Preview
United Therapeutics Corporation develops and commercializes therapies for patients with chronic and life-threatening conditions, primarily focused on pulmonary arterial hypertension (PAH) through its flagship products Tyvaso, Remodulin, Orenitram, and Unituxin. The company's diversified PAH portfolio and pipeline expansion into organ transplantation make it a key player in rare disease therapeutics.
UTHR reports Q2 2026 earnings before market open on Wednesday, August 5, 2026, with the consensus estimate at $6.82 per share from 5 analysts. The estimate range spans $6.07 to $7.48, reflecting some uncertainty around the quarter's performance. Most recently, the company reported $5.82 per share for Q1 2026, a significant miss that fell 13.52% short of the $6.73 consensus. Year-over-year, the $6.82 estimate represents +6.40% growth versus the $6.41 reported in Q2 2025, suggesting analysts expect a return to modest expansion.
Three key themes define this earnings story:
1. Recovery from Q1's Sharp Miss: Last quarter's 13.52% earnings shortfall marked a notable stumble after two consecutive strong beats. Investors will scrutinize whether operational issues were temporary or signal deeper challenges in the PAH market or competitive dynamics.
2. Tyvaso Franchise Momentum: As UTHR's growth engine, Tyvaso's performance—particularly the DPI (dry powder inhaler) formulation—remains critical. Any commentary on market share gains, patient adoption trends, or pricing dynamics will move the stock.
3. Pipeline Progress and Organ Transplantation: Beyond PAH, UTHR's investments in xenotransplantation and organ manufacturing represent long-term optionality. Updates on clinical milestones or regulatory pathways could provide upside catalysts independent of near-term earnings.
Analyst commentary ahead of the release reflects cautious optimism. The 9 Strong Buy ratings (out of 15 total) suggest conviction in the long-term story, but the recent downgrade in Barchart's technical opinion from 56% Buy to 24% Sell signals near-term concern. The mean price target of $663.28 implies 27.9% upside from current levels, indicating analysts view any weakness as a buying opportunity for the franchise's durability.
Part 2: Historical Earnings Performance
United Therapeutics has delivered a mixed earnings track record over the past four quarters, with two beats and two misses creating an inconsistent pattern. The company posted strong positive surprises in Q3 2025 (+3.92%) and Q4 2025 (+13.57%), demonstrating operational leverage when execution aligns. However, bookending misses in Q2 2025 (-5.74%) and Q1 2026 (-13.52%) reveal vulnerability to quarterly volatility.
The most recent quarter stands out as particularly concerning—the -13.52% miss in Q1 2026 represented the largest shortfall in this window and broke a two-quarter winning streak. Prior to that, Q4 2025's +13.57% beat ($7.70 vs. $6.78 estimate) had been the strongest performance, suggesting the business can deliver meaningful upside when conditions are favorable. The pattern suggests UTHR's earnings are sensitive to factors like product mix, pricing, and timing of shipments rather than following a predictable trajectory.
Looking at the absolute EPS progression, reported results have ranged from $5.82 (Q1 2026) to $7.70 (Q4 2025), highlighting significant quarter-to-quarter swings. The upcoming $6.82 estimate would represent a sequential recovery from Q1's weakness but still falls short of the prior two quarters' results, indicating analysts are modeling a normalization rather than a return to peak performance.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $6.80 | $6.41 | -5.74% | Miss |
| Sep 2025 | $6.89 | $7.16 | +3.92% | Beat |
| Dec 2025 | $6.78 | $7.70 | +13.57% | Beat |
| Mar 2026 | $6.73 | $5.82 | -13.52% | Miss |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
United Therapeutics typically reports earnings before market open, meaning Day 0 captures the market's immediate reaction during the first trading session, while Day +1 reflects follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-06 | +$24.56 (+4.29%) | $34.35 (6.00%) | -$27.58 (-4.62%) | $30.25 (5.07%) |
| 2026-02-25 | +$61.67 (+13.03%) | $59.06 (12.47%) | -$31.50 (-5.89%) | $35.81 (6.69%) |
| 2025-10-29 | +$39.98 (+9.63%) | $64.24 (15.47%) | -$1.79 (-0.39%) | $10.88 (2.39%) |
| 2025-07-30 | -$15.61 (-5.25%) | $20.14 (6.77%) | -$7.25 (-2.57%) | $11.88 (4.21%) |
| 2025-04-30 | +$2.33 (+0.77%) | $26.37 (8.77%) | -$9.24 (-3.05%) | $12.27 (4.05%) |
| 2025-02-26 | -$38.61 (-10.80%) | $37.43 (10.47%) | +$4.73 (+1.48%) | $11.67 (3.66%) |
| 2024-10-30 | +$8.60 (+2.44%) | $18.46 (5.23%) | +$12.57 (+3.48%) | $15.47 (4.28%) |
| 2024-07-31 | -$24.25 (-7.18%) | $15.99 (4.74%) | +$14.50 (+4.63%) | $17.98 (5.74%) |
| Avg Abs Move | 6.67% | 8.74% | 3.26% | 4.51% |
UTHR exhibits substantial post-earnings volatility, with Day 0 moves averaging 6.67% in absolute terms and ranging as high as 13.03% (February 2026's strong beat). The stock has moved in both directions—four positive Day 0 reactions and four negative—with no clear directional bias, suggesting results quality drives the response rather than systematic positioning.
The most dramatic recent move came in February 2026, when the stock surged +13.03% following a +13.57% earnings beat, demonstrating how significant upside surprises can generate outsized gains. Conversely, May 2026's -4.62% Day +1 decline (following a -13.52% miss) shows the market punishes disappointments, though the initial Day 0 reaction was muted at +4.29%, indicating delayed recognition of the miss's severity.
Day +1 follow-through averages 3.26% in absolute terms, smaller than Day 0 but still meaningful. The pattern suggests initial reactions can extend or reverse, with February 2026 seeing a -5.89% Day +1 pullback after the Day 0 surge, while July 2025 reversed a -5.25% Day 0 drop with a +4.63% Day +1 recovery. Investors should prepare for a potential swing of 6–7% on earnings day, with additional volatility possible in the following session depending on management commentary and analyst reactions.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 17) |
| Expected Move | $32.16 (6.20%) |
| Expected Range | $486.52 to $550.84 |
| Implied Volatility | 43.42% |
The options market is pricing an expected move of 6.20% ($32.16) for the August 21 expiration, closely aligned with UTHR's average historical Day 0 move of 6.67%. This suggests options traders are anticipating typical earnings volatility rather than an outsized reaction, despite last quarter's sharp miss and the stock's recent technical weakness.
Part 3: What Analysts Are Saying
Analysts maintain a bullish stance on United Therapeutics, with the consensus rating at 4.33 out of 5.00—firmly in Buy territory. The breakdown shows 9 Strong Buys, 2 Moderate Buys, and 4 Holds, with no sell ratings, reflecting confidence in the company's long-term franchise value despite near-term execution concerns.
Sentiment has remained unchanged over the past month, with rating counts holding steady at 9 Strong Buys, 2 Moderate Buys, and 4 Holds. This stability suggests analysts are looking through Q1's miss as a temporary setback rather than a fundamental deterioration, maintaining conviction in the PAH portfolio's durability and pipeline optionality.
The mean price target of $663.28 implies 27.9% upside from the current price of $518.68, with estimates ranging from a low of $516.00 (essentially flat) to a high of $750.00 (+44.6% upside). The wide target range reflects differing views on the company's growth trajectory and pipeline value, but the clustering of Strong Buy ratings indicates most analysts see the current valuation as attractive relative to the franchise's earnings power and market position.
Part 4: Technical Picture
United Therapeutics enters earnings with deteriorating technical momentum. The Barchart Technical Opinion currently stands at 24% Sell, down sharply from 56% Buy one month ago, marking a significant reversal in near-term sentiment. Last week's reading also showed 24% Sell, indicating the weakness has stabilized at cautionary levels rather than continuing to deteriorate.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative heading into the report
- Medium-term (Hold): Neutral reading suggests the intermediate trend remains in consolidation without a clear directional bias
- Long-term (Hold): Neutral signal reflects a balanced longer-term technical picture despite recent weakness
Trend Characteristics: The trend is showing Minimum strength with a Weakening direction, suggesting technical support is fragile and the stock lacks the momentum cushion that typically helps absorb negative earnings surprises.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $520.64 | 50-Day MA | $542.49 |
| 10-Day MA | $523.99 | 100-Day MA | $553.05 |
| 20-Day MA | $530.88 | 200-Day MA | $515.24 |
The stock is trading at $518.68, positioned below its 5-day ($520.64), 10-day ($523.99), 20-day ($530.88), 50-day ($542.49), and 100-day ($553.05) moving averages, but above its 200-day moving average ($515.24). This configuration—below all short- and intermediate-term averages but clinging to long-term support—paints a cautionary picture. The downward slope across the moving average stack indicates a stock in retreat, with the 200-day average serving as the last line of defense. Given the weak technical setup, UTHR will need a strong earnings beat and positive guidance to reverse the momentum—a miss or cautious outlook could accelerate the decline toward the $486.52 lower bound of the options expected move range.
